YAM80(YAM80) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病

在研适应症-

非在研适应症

肌萎缩侧索硬化

原研机构

Yoshino Neurology Clinic

在研机构-

非在研机构

Yoshino Neurology Clinic

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 YAM80 相关的临床试验

NCT00886977 / Unknown status临床2期IIT

Pilot-Study of YAM80 in Amyotrophic Lateral Sclerosis. Evaluation of the Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)

The efficacy and safety are evaluated when YAM80 is administered orally to the patients of Amyotrophic Lateral Sclerosis (ALS).

开始日期2009-04-01

申办/合作机构

Yoshino Neurology Clinic

100 项与 YAM80 相关的临床结果

登录后查看更多信息

100 项与 YAM80 相关的转化医学

登录后查看更多信息

100 项与 YAM80 相关的专利（医药）

登录后查看更多信息

1

项与 YAM80 相关的文献（医药）

2005-04-01·Clinical calcium

[Management of glucocorticoid-induced osteoporosis].

Review

作者: Soen, Satoshi

Osteoporosis is the most frequent adverse effect observed during glucocorticoids therapy. The 2004 edition of the guideline on the management and treatment of glucocorticoid-induced osteoporosis has been proposed by The Japanese Society for Bone and Mineral Research. The subjects were patients with using or planning to use oral glucocorticoids for 3 months or longer. The criterion for starting treatment consisted patients with prior fragility fracture and with new fractures during treatment, patients with less BMD than %YAM80, and patients with using as a dose of 5 mg/day or higher (mean daily dose) as prednisolone equivalent. The Bisphosphonates have been recommended as first-line drugs. Active vitamin D3 and vitamin K2 have been recommended as second-line drugs.

100 项与 YAM80 相关的药物交易

登录后查看更多信息